CTOs on the Move

Context Therapeutics

www.contexttherapeutics.com

 
Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

DeliverIt Pharmacy

The new and innovated concept of DeliverIt Pharmacy came from our 20 years of experience. We have seen it all, the frustrations and hassles customers have to go through just to get their prescription. At DeliverIt Pharmacy we strive to keep the balance of affordable and convenience for our customers while performing proficiently and efficiently. We conveniently offer a variety of ways for you to get your prescription such as delivery, drive-thru, and walk-in pickup so there`s no frustrating long-lines to wait in. This will allow you to spend more time with your family, or return to your busy schedule of work or school! We offer compounding, which allows us to work with your physician to customized your prescription to your individual needs. We care for your love one`s well-being just as much as you do! Whether it`s your children, parents, or pets! We offer a variety of methods to make it easier for you to get them to comply with their medication

Dicerna

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.

Acerta Pharma B.V.

Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer.

Regulatory and Clinical Research Institute

Regulatory and Clinical Research Institute is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.